Anti-calcium drug blocks cervical cancer in mice

	Tweet

Treatment with Zometa (zoledronic acid), a drug used to reduce high calcium levels, can block the development of cervical cancer in mice, according to a report in the Journal of Clinical Investigation.

Because the mouse type of cancer resembles the kind seen in humans, lead author Dr. Douglas Hanahan and colleagues, from the University of California, San Francisco, consider Zometa a promising treatment for cervical cancer and related diseases.

In their studies, Zometa blocked blood vessel formation in the early growths that progress to cervical cancer as well in the cancer itself. Without adequate blood supply, these growths are essentially stopped dead in their tracks.

Based on Zometa’s ability to inhibit early lesions and given its track record of safety, the authors suggest that it might be useful in preventing disease recurrence in high-risk women who have undergone surgery.

Also, with its ability to interfere with established cervical cancers, perhaps Zometa could become a standard treatment for this disease, the authors note. Clearly, more study is needed, they add.

SOURCE: Journal of Clinical Investigation, September 2004.

RELATED STORIES:
Celebrex not as bad for heart as Vioxx   Glaxo hopes for pandemic flu vaccine by yr-end   Only Buy buspar 10mg From The Best Online Pharmacies   Shortage of Cancer Drugs Impacts Iraqi Children with Leukemia   FDA grants fast track status for ViroPharma’s Maribavir   Canada health panel says Vioxx pain drug safe enough   Drug use in strict Singapore waning, gov’t says   Health advisers revive Merck’s Vioxx   Buying drugs online can be risky - report   FDA wants asthma drug withdrawn   Swedish chain challenges state drug sale monopoly   Research opens door to vaccines that can circumvent maternal antibodies

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]